Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIZEM LA vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Chronic stable angina pectoris,Atrial fibrillation or atrial flutter (rate control),Paroxysmal supraventricular tachycardia (PSVT)
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life: 5-8 hours after oral administration. For extended-release formulations, the half-life is similar but the prolonged absorption phase results in sustained plasma concentrations.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites include N-desmethyl diltiazem (active), deacetyl diltiazem, and others.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Urine (2-4% unchanged, ~40% as metabolites); bile/feces (major route, ~60% as metabolites).
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
70-80% bound to plasma proteins (mainly albumin).
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
3-5 L/kg, indicating extensive tissue distribution.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: ~40% due to extensive first-pass metabolism; intravenous: 100%.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No specific dose adjustment is required for decreased GFR; however, use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy have not been established in pediatric patients; no standard pediatric dosing available.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Initiate at low end of dosing range (180 mg once daily) and titrate slowly due to increased risk of hypotension, bradycardia, and reduced hepatic clearance.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None.
None
Conduction abnormalities: May worsen sinus node dysfunction or AV block, especially in elderly or with beta-blockers.,Heart failure: Use with caution in patients with reduced left ventricular function.,Hypotension: May cause symptomatic hypotension, especially with concurrent vasodilators.,Hepatic impairment: Diltiazem is hepatically metabolized; use with caution in patients with hepatic impairment.,Abrupt withdrawal: May precipitate angina or hypertension exacerbation; taper dose.,Beta-blocker coadministration: Increased risk of bradycardia, AV block, and hypotension.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (unless pacemaker present),Second- or third-degree AV block (unless pacemaker present),Systolic blood pressure <90 mm Hg,Acute myocardial infarction with pulmonary congestion,Known hypersensitivity to diltiazem,Concurrent use with rifampin (enzyme inducer reduces effectiveness)
None
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase diltiazem levels. Limit alcohol intake due to additive vasodilation and hypotension risk. No specific food restrictions otherwise, but maintain a heart-healthy diet low in sodium and saturated fats to support blood pressure and angina management.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Category C. First trimester: No adequate studies in humans; animal studies show embryotoxicity and fetotoxicity at high doses. Second and third trimesters: Risk of fetal bradycardia, hypotension, and growth restriction; avoid use if possible.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted in breast milk; M/P ratio not established. Limited data suggest low levels; however, monitor infant for bradycardia, hypotension, and feeding difficulties. Use with caution.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No standard dose adjustment; pharmacokinetic changes (increased volume of distribution, altered protein binding) may necessitate titration based on clinical response. Avoid in first trimester if possible.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
CARDIZEM LA is a once-daily extended-release formulation of diltiazem, a non-dihydropyridine calcium channel blocker. It is useful for hypertension and chronic stable angina. Avoid use in patients with second- or third-degree AV block, sick sinus syndrome without pacemaker, hypotension (SBP <90 mm Hg), or acute MI with pulmonary congestion. Monitor heart rate and PR interval, as it can cause bradycardia and AV block. Contraindicated with IV beta-blockers; caution with oral beta-blockers due to additive negative chronotropic effects. CYP3A4 substrate; avoid strong inhibitors/inducers. Do not crush or chew capsules; can sprinkle contents on applesauce for patients with swallowing difficulties. Max antihypertensive effect may take 2 weeks. Withdrawal may cause angina exacerbation; taper if discontinuing. Use with caution in heart failure with reduced ejection fraction (HFr EF) due to negative inotropic effects.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take exactly as prescribed, usually once daily. Swallow capsule whole; do not crush or chew. If you have trouble swallowing, you may open the capsule and sprinkle the beads on a spoonful of applesauce; swallow immediately without chewing.,This medication helps lower blood pressure and reduce chest pain (angina). It may take up to 2 weeks to see the full effect on blood pressure. Keep taking it even if you feel well.,Avoid drinking grapefruit juice or eating grapefruit while taking this medication as it can increase side effects.,Common side effects include swelling in legs/ankles, headache, dizziness, or flushing. Report slow heartbeat, severe dizziness, fainting, or shortness of breath to your doctor.,Do not stop taking this medication suddenly, as it may worsen chest pain or cause a heart attack. Your doctor will tell you how to taper the dose if needed.,Limit alcohol consumption, as it may increase dizziness or lower blood pressure further.,Inform all healthcare providers you are taking CARDIZEM LA, especially before surgery or dental procedures.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIZEM LA vs AMVAZ, answered by our medical review team.
CARDIZEM LA is a Calcium Channel Blocker that works by Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIZEM LA and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIZEM LA is: Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIZEM LA and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIZEM LA is classified as Category C. Category C. First trimester: No adequate studies in humans; animal studies show embryotoxicity and fetotoxicity at high doses. Second and third trimesters: Risk of fetal bradycardi. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.